ストックスクリーナーアプリを入手
13.54
0.15%
0.02
プレマーケット:
13.54
Organon Co (OGN) 最新ニュース
India healthcare M&A hits record value as pharma takes centre stage - DealStreetAsia
OGN Looks 6.8% Undervalued on GF Value™ - GuruFocus
OGN|Organon & Co|Price:13.535|Chg%:+0.015 - TradingKey
Organon & Co (OGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Organon & Co. (OGN) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
OGN|Organon & Co|Price:13.520| - TradingKey
Organon & Co (OGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Organon & Co (OGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Organon & Co. (OGN) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (OGN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
India’s pharma M&A market hits four-year high on blockbuster deals - The Pharma Letter
Sun Pharma Clears Key Milestone as Organon Shareholders Back USD 11.75 Billion Buyout - Medical Dialogues
OGN|Organon & Co|Price:13.520|Chg%:-0.035 - TradingKey
Sun Pharma Receives Organon Shareholder Approval for Proposed Acquisition - Machine Maker
OGN Stock Set For Blastoff? Sun Pharma Offers 24% Premium In All-Cash Buyout Deal - Stocktwits
Organon & Co. (OGN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon shareholders approve Sun Pharma acquisition proposal - Indian Pharma Post
Organon & Co. (OGN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (OGN) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (OGN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Organon & Co. (1OGN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
New Analysis of Phase 3 Pooled Data for Organon's VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1 - Lelezard
Organon's VTAMA Skin-Clearance Response Reached 56.3% in Ages 2–6 at Week 8 - Stock Titan
Sun Pharma gets Organon shareholders’ nod for its $11.75-bn acquisition proposal - BusinessLine
Organon & Co. (OGN) 8-K Filing: Key Stockholder Vote Results and Company Information – July 2026 - Minichart
Organon shareholders approve merger with Sun Pharma - Fortune India
Organon Shareholders Approve Sun Pharma Merger, Deal Nears Completion - outlookbusiness.com
Sun Pharma Stock Slips as Organon Holders Approve Merger - Equitypandit
Organon shareholders approve Sun Pharma's $11.75-bn acquisition proposal - The Economic Times
Organon Shareholders Approve Sun Pharma’s USD 11.75-bn Acquisition Proposal - HDFC Sky
Sun Pharma Moves Closer To Record $12 Billion Organon Deal After Shareholders Approval - NDTV Profit
Sun Pharma inches closer to biggest-ever buyout as Organon shareholders approve merger - Moneycontrol.com
Sun Pharma receives Organon shareholders approval for merger - Business Standard
Sun Pharma moves closer to Organon acquisition as shareholders approve deal; stock in focus - Upstox
Organon Shareholders Endorse Merger with Sun Pharmaceutical Holdings USA in July 2026 Vote - Kalkine Media
Organon & Co. Shareholders Clear Sun Pharma Merger Deal - Yahoo Finance
Organon & Co (OGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Organon (OGN) Stock Looks Below Fair Value Despite Weak Earnings Quality - simplywall.st
Organon (OGN) Proxy filing Summary - Quartr
ORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BÉGIN AS PRESIDENT AND MANAGING DIRECTOR - marketscreener.com
Press Release: ORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BÉGIN AS PRESIDENT AND MANAGING DIRECTOR - Moomoo
Sun Pharma to acquire US-based Organon in nearly $11.75 billion deal - DD News
Price-Driven Insight from (OGN) for Rule-Based Strategy - Stock Traders Daily
Organon stock trades steady as women’s health focus meets mixed earnings momentum - Ad-hoc-news.de
XS233225070 Bond Profile — Key Metrics - TradingView
Organon Faces Legal Challenge Over Merger Proxy Disclosures Ahead of Shareholder Vote - Kalkine Media
[8-K] Organon & Co. Reports Material Event - Stock Titan
Samsung Bioepis and Organon expand biosimilar commercialisation agreement in Australia - BioSpectrum Asia
Organon to report Q2 2026 results, suspends earnings calls - scanx.trade
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing - Business Wire
Samsung Bioepis and Organon broaden biosimilar access in Australia - The Pharma Letter
What Sparked Organon's Recent Stock Surge - Kavout | AI
Samsung Bioepis, Organon expand biosimilar partnership in Australia - koreabiomed.com
Samsung Bioepis and Organon Broaden Biosimilar Access in Australia - Businesskorea
MRK5808585 Bond Profile — Key Metrics - TradingView
Organon & Co. (OGN) is a trending stock: Facts to know before betting on it - MSN
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Organon & Co.: Great Odds, Small Prize, Big Penalty (NYSE:OGN) - Seeking Alpha
0.53%
大文字化:
|
ボリューム (24 時間):